Harvard lands $50M for translational drug projects; FDA approves Kcentra to control warfarin-related bleeding;

@FierceBiotech: From FierceBiomarkers.com: Brain atrophy could predict multiple sclerosis, study finds. More | Follow @FierceBiotech

@JohnCFierce: Henri Termeer is joining the board at Moderna (big pact with AstraZeneca). Moderna gets my vote for fast co. status. I hope they pull it off. | Follow @JohnCFierce

@RyanMFierce: Sanofi teams with BigData outfit NextBio to research drugs for diabetes and cancer. More | Follow @RyanMFierce

> Harvard University has landed a $50 million gift to finance the Blavatnik Biomedical Accelerator, which will spur along translational medicine by finding promising therapeutic programs and putting them on the path to a possible approval. Story

> The FDA has approved Kcentra, a new drug designed to reverse the effects of warfarin and control the bleeding risks associated with the old drug. Story

> Expanding from small molecules to biologics, San Diego-based Ligand Pharmaceuticals ($LGND) has snapped up a portfolio of future milestone and royalty payments for more than 15 biologic programs from Selexis. Release

Medical Device News

@FierceMedDev: Experts: Taiwan, Israel should form med device alliance. Item | Follow @FierceMedDev

@MarkHFierce: Today's DxExtra: LipoScience is moving head with development of a cardiovascular Dx that relies on gut flora. More | Follow @MarkHFierce

 @DamianFierce: HeartWare's sales leapt 87% in Q1 thanks to a successful U.S. ventricular pump launch. Article | Follow @DamianFierce

> Asthma devicemaker Aerocrine nabs $50M. More

> German court sides with Boston Scientific rival in stent patent fight. Article

> Qiagen buys Ingenuity Systems for $105M. News

Pharma News

@FiercePharma: Pfizer stock down on Q1 shortfall, lowered profits forecast. Sales down 9% to $13.5B. EPS expected at up to $2.24 now, down from $2.30. Results statement | Follow @FiercePharma

@EricPFierce: Novartis to expanded Swiss OTC plant while taking ax to its troubled consumer facility in Lincoln, NE. Article | Follow @EricPFierce

> Pfizer cuts forecast as Q1 sales fall $550M short of estimates. News

> Regeneron execs score $140M payday as Eylea mints money. Article

> Merck wins bellwether Fosamax femur-fracture trial. More

Biotech Research News

 @EmilyMFierce: Investigators explore inflammation's role in Parkinson's development. Article | Follow @EmilyMFierce

> Malaria parasite protein could be used to prevent disease transmission. Item

> Gilead drug clears hep B virus in chimpanzees. More

> Zoonotic virus kills human melanoma cells in animal model. Story

> Harvard scientists discover hormone that could treat diabetes. Article

Pharma Manufacturing News

> FDA uncovers foreign-made Botox disguised as U.S. product. News

> Alexion brings in hired guns for troubled plant. Article

> Lonza API plant problems undermine Ipsen's Increlex supplies. More

> Blocking a gene's activity could clear beta-amyloid plaques in Alzheimer's. Story

And Finally… The death of an 89-year-old man from a new strain of bird flu has brought the death toll in Shanghai to 13, the highest of any Chinese city. The city is a global business hub, which has also attracted a number of major biopharma operations. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.